Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

SIMPLE SUMMARY: Patients with stage IIB-IV melanoma who have had surgery are recommended to receive systemic adjuvant therapy, intended to target the residual micro-metastatic disease and reduce the risk of melanoma relapse and death from melanoma. Multiple adjuvant therapy regimens have been tested...

Descripción completa

Detalles Bibliográficos
Autores principales: Eljilany, Islam, Castellano, Ella, Tarhini, Ahmad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453009/
https://www.ncbi.nlm.nih.gov/pubmed/37627153
http://dx.doi.org/10.3390/cancers15164125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453009/
https://www.ncbi.nlm.nih.gov/pubmed/37627153
http://dx.doi.org/10.3390/cancers15164125

Ejemplares similares